Related content

Dopamine receptor agonists in the therapy of Parkinson’s disease

By Foley P.   Gerlach M.   Double K. L.   Riederer P.  

Journal of Neural Transmission, Vol. 111, Iss. 10-11, 2004-10 ,pp. : 1375-1446

Springer Publishing Company

Access to resources Recommend Favorite

Usefulness of switching to cabergoline from other dopamine agonists in patients with advanced Parkinson’s disease

By Shiraishi M.   Kamo T.   Hotta M.   Nemoto S.   Oshima J.   Sugihara H.   Yasaki S.   Kawakami M.   Takahashi Y.   Shimojo S.  

Journal of Neural Transmission, Vol. 111, Iss. 6, 2004-06 ,pp. : 725-732

Springer Publishing Company

Access to resources Recommend Favorite

Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson’s disease from essential tremor

By Pellicano C.   Buttarelli F. R.   Circella A.   Tiple D.   Giovannelli M.   Benincasa D.   Colosimo C.   Pontieri F. E.  

Journal of Neural Transmission, Vol. 114, Iss. 7, 2007-07 ,pp. : 935-938

Springer Publishing Company

Access to resources Recommend Favorite

Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson’s disease

By Levy R.  

Brain, Vol. 125, Iss. 6, 2002-06 ,pp. : 1196-1209

Oxford University Press

Access to resources Recommend Favorite

Pathological gambling in two patients on dopamine replacement therapy for Parkinson’s disease

By Avanzi M.   Uber E.   Bonfà F.  

Neurological Sciences, Vol. 25, Iss. 2, 2004-06 ,pp. : 98-101

Springer Publishing Company

Access to resources Recommend Favorite